Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: March 2006

VistaGen Therapeutics (VSTA) and CATO BioVentures Sign Strategic Business Development Agreement for CNS Products

VistaGen Therapeutics Inc., a biopharmaceutical company applying leading embryonic stem cell technology to discover and develop novel treatments for central nervous system disorders, diabetes and cardiovascular disease, and Cato BioVentures, the venture capital affiliate of Cato Research Ltd., a global … Continue reading

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment